In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389855PMC
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619DOI Listing

Publication Analysis

Top Keywords

antibodies sars-cov-2
8
navarre spain
8
anti-n antibodies
8
seroprevalence antibodies
4
sars-cov-2 risk
4
risk covid-19
4
covid-19 navarre
4
spain july
4
july 2022
4
2022 navarre
4

Similar Publications

The growing body of experimental and computational studies suggested that the cross-neutralization antibody activity against Omicron variants may be driven by balance and tradeoff of multiple energetic factors and interaction contributions of the evolving escape hotspots involved in antigenic drift and convergent evolution. However, the dynamic and energetic details quantifying the balance and contribution of these factors, particularly the balancing nature of specific interactions formed by antibodies with the epitope residues remain scarcely characterized. In this study, we performed molecular dynamics simulations, ensemble-based deep mutational scanning of SARS-CoV-2 spike residues and binding free energy computations for two distinct groups of broadly neutralizing antibodies : E1 group (BD55-3152, BD55-3546 and BD5-5840) and F3 group (BD55-3372, BD55-4637 and BD55-5514).

View Article and Find Full Text PDF

Objective: We previously found that per- and polyfluoroalkyl substances (PFAS) mixture exposure is inversely associated with SARS-CoV-2 IgG (IgG) antibody levels in pregnant individuals. Here, we aim to identify metabolites mediating this relationship to elucidate the underlying biological pathways.

Methods: We included 59 pregnant participants from a US-based pregnancy cohort.

View Article and Find Full Text PDF

Immunogenicity of the CoronaVac vaccine in children: a real-world study.

Front Immunol

December 2024

Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, Colombia.

Background: Despite its proven effectiveness and safety, there are limited real-world data on CoronaVac's immunogenicity in children, especially in lower-income countries, particularly for SARS-CoV-2 variants. We present a real-world study evaluating CoronaVac's immunogenicity in Colombian children stratified by previous exposure to this virus.

Methods: 89 children aged 3-11 years were enrolled (50 Non-Exposed and 39 Exposed).

View Article and Find Full Text PDF

Detection of biomarkers associated with physiological conditions provides critical insights into healthcare and disease management. However, challenges in sampling and analysis complicate the detection and quantification of protein biomarkers within the epidermal layer of the skin and in viscous liquid biopsy samples. Here, we present the "Lab-on-the-Needles" concept, utilizing a microneedle patch-based sensing box (MNP-based SenBox) for mobile healthcare applications.

View Article and Find Full Text PDF

Background And Aims: Dried blood spots (DBS) have been proposed as a cost-effective surveillance method for population-wide screening of SARS-CoV-2 immunity but sensitivity of DBS based on self-collected DBS samples is unknown. To evaluate the success of vaccination strategies, it is necessary to differentiate vaccination from natural infection. Therefore, a test for antibodies against the viral nucleocapsid protein (anti-N) is desirable.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!